Hiscoperindopril and indapamide tablets enter administrative approval and will win the first imitation of compound antihypertensive drugs

Recently, Haisco has entered the administrative approval stage with the imitation of perindopril indapamide tablets reported for production in Category 4 and is expected to win the first imitation

Perindopril and indapamide is a compound antihypertensive drug developed by French Servier.

According to data from Meinenet, in 2020, the total sales of perindopril and indapamide in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 3 100 million yuan

At the physical pharmacy terminals in Chinese cities, the sales of perindopril and indapamide have been rising steadily, from 34.

Sales of perindopril and indapamide in physical pharmacies in cities in China (unit: ten thousand yuan)

Source: Mi Nei.

At present, only Servier has been approved for production of perindopril indapamide tablets in the domestic market, and Menova Tiankang and Haisco have submitted applications for perindopril indapamide tablets in imitation 4 categories

Data source: Mi Neiwang database, NMPA